Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31149440 | 0.87 | SMN1; SMN2 (0.51) | TSHRSMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL27556300 | 0.86 | ALDH1A1 (0.51) | TSHRSMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL6559718 | 0.86 | ALDH1A1 (0.51) | TSHRSMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL5186550 | 0.84 | ALDH1A1 (0.50) | TSHRSMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL7030449 | 0.84 | CA12 (0.48) | SMN1; SMN2MEN1HTTKMT2AHPGD | |
| SCHEMBL2021869 | 0.83 | HCAR2 (0.54) | TSHRSMN1; SMN2HPGDALDH1A1TDP1 | |
| SCHEMBL27489982 | 0.83 | HCAR2 (0.60) | TSHRSMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL22283432 | 0.83 | TSHR (0.53) | TSHRSMN1; SMN2KMT2AALDH1A1TDP1 | |
| SCHEMBL7030463 | 0.82 | IDO1 (0.52) | TSHRSMN1; SMN2 | |
| SCHEMBL6247246 | 0.82 | TDP1 (0.50) | TSHRSMN1; SMN2MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838697-B2 | Manufacturing method of organoboron compound | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20080262257-A1 | MANUFACTURING METHOD OF ORGANOBORON COMPOUND | NIPPON CHEMICAL INDUSTRIAL CO., LTD (JP) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262257-A1 | MANUFACTURING METHOD OF ORGANOBORON COMPOUND | SQLE, ICOSLG, GRB7 | TSHR 2053/4885SMN1; SMN2 2007/4885MEN1 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.